Reply to F. Muntoni et al.: "In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy

J Neuromuscul Dis. 2023;10(6):1155-1157. doi: 10.3233/JND-239005.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter